Latest Regulatory Milestones News

VHM Limited has launched a partially underwritten equity placement and share purchase plan to fund the development of its Goschen rare earths and mineral sands project, targeting production by late 2026.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

AVITA Medical reveals a bold expansion plan targeting a $3.5 billion U.S. acute wound care market by 2025, driven by a multi-product portfolio and sustained revenue growth.

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Silex Systems reports steady progress on its TRL-6 uranium enrichment demonstration, targeting completion by end-2025, while securing initial US government funding to support commercialisation efforts.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

TechGen Metals Limited is advancing exploration with a +4,000m aircore drilling program at El Donna and multiple geophysical and sampling campaigns across Western Australia and New South Wales.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Dateline Resources has gained critical U.S. regulatory approval for its Colosseum Gold-REE Project, unlocking rare earth exploration rights and pursuing an OTCQB listing to engage American investors.